Boston Life Sciences announces plans for Phase III clinical trial for THERAFECTIN(R).WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 21, 1995--Boston Life Sciences Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BLSI BLSI Boston Life Sciences, Inc. ) announced that it has submitted to the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. a draft protocol for a proposed Phase III study of THERAFECTIN(R) (amiprilose HCl), a potential oral drug for the treatment of rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. . The draft protocol is for a double-blind, placebo-controlled, multi-center study similar to a successful Phase III study previously performed by Greenwich Pharmaceuticals, the original developer of the drug. BLSI obtained THERAFECTIN as a consequence of its merger with Greenwich Pharmaceuticals Inc. in June 1995. "We have designed this study to be similar to Greenwich's successful RA-9 study, with the goal of replicating the positive results that were achieved for THERAFECTIN in that Study. We feel that if statistically significant positive results are obtained from this study, we will have confirmation of the efficacy of THERAFECTIN for the treatment of rheumatoid arthritis," stated Marc E. Lanser M.D., chief scientific officer of BLSI. BLSI is developing novel treatments for cancer, autoimmune diseases, and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . BLSI's products include among others, Cartilage-derived Inhibitor (CDI CDI compact disc interactive: a system for storing a mix of software, data, audio, and compressed video for interactive use under processor control ), a natural anti-angiogensis factor for the treatment of solid tumors; Axogenesis Factor 1 (AF-1), a novel central nervous system growth factor; Altropane(TM), a radioimaging agent for the diagnosis of Parkinson's Disease; and a transcription factor that controls the expression of molecules associated with autoimmune disease. CONTACT: Boston Life Sciences Inc. Marc E. Lanser, 617/890-8263 George A. Eldridge, 617/890-8263 or H.L. Lanzet Inc. Herbert Lanzet, 212/687-0061 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion